4 Science Park
About Precipio DiagnosticsPrecipio is the only diagnostics company to address the challenges of disease misdiagnosis, and bring a solution to the clinical world. We have successfully combined the experience, knowledge and expertise of academic-level pathology, with commercial-level service. Physicians around the world benefit from direct access to the highest quality of diagnostic support, coupled with rapid and efficient service, needed to battle cancer.
CEO: Ilan Danieli
CSO: Jeffrey Sklar
Please click here for Precipio job opportunities.
29 articles with Precipio Diagnostics
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular PanelPanel of clinically critical genes can yield same-day results outperforming major competitors
- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced today that it has launched its HemeScreen™ AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This new panel expands the HemeScreen offering for reference laboratories and physician office laboratories, enabling them to provide improved patient care through faster turnaround time. Mo
Precipio Announces Q2-2020 Corporate Update Call For ShareholdersConference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2020 corporate update call on Monday, August 17 th at 5:00 PM ET. The call will include updates on the company’s current core businesses, as well as an update on the company’s COVID-19 testing initiative. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Pre
Precipio Launches Covid-19 Antibody Test in its CLIA laboratoryTest initially offered to Precipio’s customer base, then expanding distribution reach
Specialty diagnostics company Precipio, Inc., announced it has completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory, and has launched the test commercially to its pathology customer base.
Precipio Announces Commercial Launch of COVID-19 Antibody TestTest received FDA EUA; commercialization begins
Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), is announcing its COVID-19 strategy, and its intent to contribute to the battle against the ensuing worldwide pandemic. Today, the company announced it entered into an agreement with ADS Biotec , a US company based in Omaha, Nebraska, to distribute its FDA-authorized COVID-19 serology antibody tests that recently received EUA (Emergency Use Authorization). Distribution of
Specialty diagnostics company Precipio, Inc., announced that it has regained compliance with the Nasdaq listing requirements.
Precipio Adds Another HemeScreen™ CustomerNewly Created Reagent Rental Program Continues to Gain HemeScreen Adopters
- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted Precipio’s HemeScreen technology to launch molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). As part of Precipio’s recently launched Reagent Rental program, CHCWM’s laboratory is in the process of validati
Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2MPrecipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume
Specialty cancer diagnostics company Precipio, Inc., filed its form 10Q for the period ending March 31st, 2020.
Groundbreaking clinical and economic impact to be generated NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that preliminary results from its artificial intelligence (AI) initial MVP (Minimal Viable Product) model demonstrate a profound clinical value. The next phase is to develop a working platform expected to become commercial within the next 12-18 months. Background The diagnosis of hematopoietic
Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership that includes, among other transactions, the acquisition of the customer base of Poplar’s Hematopathology division, OncoMetrix . The planned transaction contemplates that Precipio will assume responsibility for OncoMetrix's customer base and associated reve
The management team of Specialty diagnostics company Precipio, Inc., would like to provide an explanation on the recent Amendment to the S-1 that was filed yesterday, on January 27, 2020.
The management team of Specialty diagnostics company Precipio, Inc., would like to provide several clarification points related to the recent S-1 that was filed yesterday, on January 14, 2020
The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760).
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Trials underway at five laboratories and two diagnostic equipment companies
New test fulfills promise of liquid biopsies to cost effectively monitor patients.
First post-merger quarter to turn the corner and demonstrate growth.
The adoption of liquid biopsies is expected to revolutionize cancer care, with an estimated market of $26B annually.
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pe...
1/22/2018The market for cytogenetics media is estimated to exceed $100M annually.